Skip to main content
Top
Published in: Abdominal Radiology 4/2013

01-08-2013

Gadofosveset-enhanced MRI for the assessment of rectal cancer lymph nodes: predictive criteria

Authors: Doenja M. J. Lambregts, Luc A. Heijnen, Monique Maas, Iris J. G. Rutten, Milou H. Martens, Walter H. Backes, Robert G. Riedl, Frans C. H. Bakers, Vincent C. Cappendijk, Geerard L. Beets, Regina G. H. Beets-Tan

Published in: Abdominal Radiology | Issue 4/2013

Login to get access

Abstract

Purpose

To confirm the use of the nodal signal intensity (SI) and the ‘chemical shift’ artefact as diagnostic criteria for detecting nodal metastases from rectal cancer on gadofosveset contrast-enhanced MRI.

Methods

Thirty-three patients underwent a non-enhanced and gadofosveset-enhanced 3D-T1W GRE-MRI at 1.5T. For each lymph node, the SI of the middle part of the node (mSI) and white rim of the chemical shift artefact encircling the node (wSI) were measured on the non-enhanced and gadofosveset-enhanced images. Second, the aspect of the chemical shift artefact encircling the nodes was scored using a 4-point scale. Results were compared with histology on a node-by-node basis.

Results

289 nodes (55 N+) were analysed. On gadofosveset-MRI, mSI and wSI were significantly higher for the benign than for the metastatic lymph nodes (p < 0.001). Areas under the ROC curve (AUC) for identification of metastases were 0.74 (mSI) and 0.73 (wSI). The chemical shift criterion rendered an AUC of 0.85. The combination of mSI and the chemical shift criterion resulted in an AUC of 0.88 and the rendered an AUC of 0.86–0.92 when subjectively (visually) assessed by two independent readers.

Conclusions

Benign lymph nodes show significant contrast enhancement after gadofosveset injection, while metastatic nodes do not. The uptake of gadofosveset in the nodes also affects the chemical shift artefact encircling the nodes. Combined assessment of these two features on gadofosveset-enhanced MRI provides a high diagnostic performance for diagnosing metastatic lymph nodes in patients with rectal cancer.
Literature
1.
go back to reference Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRef Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRef
2.
go back to reference Lezoche G, Baldarelli M, Guerrieri M, et al. (2008) A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc 22:352–358PubMedCrossRef Lezoche G, Baldarelli M, Guerrieri M, et al. (2008) A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc 22:352–358PubMedCrossRef
3.
go back to reference Habr-Gama A, Perez RO, Proscurshim I, et al. (2006) Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 10:1319–1328 (discussion 1328-1319)PubMedCrossRef Habr-Gama A, Perez RO, Proscurshim I, et al. (2006) Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 10:1319–1328 (discussion 1328-1319)PubMedCrossRef
4.
go back to reference Bipat S, Glas AS, Slors FJ, et al. (2004) Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging–a meta-analysis. Radiology 232:773–783PubMedCrossRef Bipat S, Glas AS, Slors FJ, et al. (2004) Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging–a meta-analysis. Radiology 232:773–783PubMedCrossRef
5.
go back to reference Lahaye MJ, Engelen SM, Nelemans PJ, et al. (2005) Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 26:259–268PubMedCrossRef Lahaye MJ, Engelen SM, Nelemans PJ, et al. (2005) Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 26:259–268PubMedCrossRef
6.
go back to reference Will O, Purkayastha S, Chan C, et al. (2006) Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 7:52–60PubMedCrossRef Will O, Purkayastha S, Chan C, et al. (2006) Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 7:52–60PubMedCrossRef
7.
go back to reference Lahaye MJ, Engelen SM, Kessels AG, et al. (2008) USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 246:804–811PubMedCrossRef Lahaye MJ, Engelen SM, Kessels AG, et al. (2008) USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 246:804–811PubMedCrossRef
8.
go back to reference Koh D-M, Brown G, Temple L, et al. (2004) Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings—initial observations. Radiology 231:91–99PubMedCrossRef Koh D-M, Brown G, Temple L, et al. (2004) Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings—initial observations. Radiology 231:91–99PubMedCrossRef
9.
go back to reference Lambregts DM, Beets GL, Maas M, et al. (2011) Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg 253:539–545PubMedCrossRef Lambregts DM, Beets GL, Maas M, et al. (2011) Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg 253:539–545PubMedCrossRef
10.
go back to reference Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, et al. (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976–1984PubMed Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, et al. (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976–1984PubMed
11.
go back to reference Lahaye MJ, Beets GL, Engelen SME, et al. (2009) Gadofosveset Trisodium (Vasovist®) enhanced MR lymph node detection: initial observations. Open Magn Resonance J 2:1–5CrossRef Lahaye MJ, Beets GL, Engelen SME, et al. (2009) Gadofosveset Trisodium (Vasovist®) enhanced MR lymph node detection: initial observations. Open Magn Resonance J 2:1–5CrossRef
12.
go back to reference Wang C, Zhou Z, Wang Z, et al. (2005) Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum. Langenbecks Arch Surg 390:312–318PubMedCrossRef Wang C, Zhou Z, Wang Z, et al. (2005) Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum. Langenbecks Arch Surg 390:312–318PubMedCrossRef
13.
14.
go back to reference Herborn CU, Lauenstein TC, Vogt FM, et al. (2002) Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model. AJR Am J Roentgenol 179:1567–1572PubMedCrossRef Herborn CU, Lauenstein TC, Vogt FM, et al. (2002) Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model. AJR Am J Roentgenol 179:1567–1572PubMedCrossRef
15.
go back to reference Yamashita T, Takahara T, Kwee TC, et al. (2011) Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment. Jpn J Radiol 29:25–32PubMedCrossRef Yamashita T, Takahara T, Kwee TC, et al. (2011) Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment. Jpn J Radiol 29:25–32PubMedCrossRef
16.
go back to reference Borschitz T, Wachtlin D, Mohler M, Schmidberger H, Junginger T (2008) Neoadjuvant chemoradiation and local excision for T2–3 rectal cancer. Ann Surg Oncol 15:712–720PubMedCrossRef Borschitz T, Wachtlin D, Mohler M, Schmidberger H, Junginger T (2008) Neoadjuvant chemoradiation and local excision for T2–3 rectal cancer. Ann Surg Oncol 15:712–720PubMedCrossRef
17.
go back to reference Maas M, Beets-Tan RG, Lambregts DM, et al. (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640PubMedCrossRef Maas M, Beets-Tan RG, Lambregts DM, et al. (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640PubMedCrossRef
Metadata
Title
Gadofosveset-enhanced MRI for the assessment of rectal cancer lymph nodes: predictive criteria
Authors
Doenja M. J. Lambregts
Luc A. Heijnen
Monique Maas
Iris J. G. Rutten
Milou H. Martens
Walter H. Backes
Robert G. Riedl
Frans C. H. Bakers
Vincent C. Cappendijk
Geerard L. Beets
Regina G. H. Beets-Tan
Publication date
01-08-2013
Publisher
Springer US
Published in
Abdominal Radiology / Issue 4/2013
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9957-4

Other articles of this Issue 4/2013

Abdominal Radiology 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.